Reference:	FOI.10777.23
Subject:	Anti-VEGF treatments and therapy
Date of Request:	25 January 2023

Requested:

1. For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:
   Aflibercept
   Bevacizumab
   Brolucizumab
   Dexamethasone
   Faricimab
   Ranibizumab - Lucentis
   Ranibizumab - Ongavia

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
   Aflibercept
   Bevacizumab
   Brolucizumab
   Dexamethasone
   Faricimab
   Ranibizumab - Lucentis
   Ranibizumab - Ongavia

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of patients that received the anti-VEGF treatments listed, during the period September to December 2022.

Treatment	Number of patients
Aflibercept	2,156
Bevacizumab	*
Brolucizumab	0
Dexamethasone	30
Faricimab	*
Ranibizumab – Lucentis	1,246
Ranibizumab – Ongavia	58

2. The UHB provides, within the table below, the number of first time patients that received the anti-VEGF treatments listed, during the period September to December 2022.

Treatment	Number of patients
Aflibercept	152
Bevacizumab	0
Brolucizumab	0

Dexamethasone	*
Faricimab	0
Ranibizumab – Lucentis	99
Ranibizumab – Ongavia	*

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact numbers, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act (FoIA).

This information is protected by the Data Protection Act 2018 and the UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/UK GDPR define personal data as data which relates to a living individual who can be identified solely from that data, or from that data and other information, which is in the possession of the data controller.